Literature DB >> 19401674

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Shan Gao1, Frederik Dagnaes-Hansen, Ebbe Juel Bech Nielsen, Jesper Wengel, Flemming Besenbacher, Kenneth Alan Howard, Jørgen Kjems.   

Abstract

Instability and inadequate biodistribution of double-stranded RNA are major drawbacks to the clinical use of RNA interference. This work compares chemical modification and nanoparticle formulation as strategies to improve the systemic delivery of small interfering RNA (siRNA). Variable levels of chemical modified siRNA, either naked or within nanoparticle, were intravenously injected into mice to study temporal stability and biodistribution detected by direct radioactive labeling or by northern blotting. Naked siRNA showed rapid renal clearance, with circulatory half-life of <5 minutes that could be extended to >30 minutes by cholesterol conjugation. The integrity of the chemically stabilized siRNA was maintained in blood for at least 30 minutes, whereas, unmodified siRNA duplex was degraded within 1 minute. Intact chemically modified siRNA could also be detected in all analyzed organs at 30 minutes but disappeared at 24 hours, except for heavy locked nucleic acid (LNA)-modified and cholesterol-conjugated siRNA in the lungs. Chitosan, liposomal, or JetPEI formulation greatly improved the stability and biodistribution of siRNA. Interestingly, high siRNA accumulation of the chitosan/siRNA formulation within the kidney was observed 24 hours postadministration. This comparative study highlights improvements to siRNA stability and pharmacokinetics, key determinants for development of clinically relevant RNAi therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401674      PMCID: PMC2835214          DOI: 10.1038/mt.2009.91

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

Review 1.  siRNAs: applications in functional genomics and potential as therapeutics.

Authors:  Yair Dorsett; Thomas Tuschl
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 2.  Polycation-based nanoparticle delivery for improved RNA interference therapeutics.

Authors:  Kenneth A Howard; Jørgen Kjems
Journal:  Expert Opin Biol Ther       Date:  2007-12       Impact factor: 4.388

Review 3.  Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.

Authors:  Achim Aigner
Journal:  J Biotechnol       Date:  2006-01-18       Impact factor: 3.307

4.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

Authors:  Fumitaka Takeshita; Yoshiko Minakuchi; Shunji Nagahara; Kimi Honma; Hideo Sasaki; Kotaro Hirai; Takumi Teratani; Nachi Namatame; Yusuke Yamamoto; Koji Hanai; Takashi Kato; Akihiko Sano; Takahiro Ochiya
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-09       Impact factor: 11.205

5.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.

Authors:  Kenneth A Howard; Ulrik L Rahbek; Xiudong Liu; Christian K Damgaard; Sys Zoffmann Glud; Morten Ø Andersen; Mads B Hovgaard; Alexander Schmitz; Jens R Nyengaard; Flemming Besenbacher; Jørgen Kjems
Journal:  Mol Ther       Date:  2006-07-10       Impact factor: 11.454

6.  Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.

Authors:  R S Geary; R Z Yu; A A Levin
Journal:  Curr Opin Investig Drugs       Date:  2001-04

7.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

Review 8.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.

Authors:  Daniele Venturoli; Bengt Rippe
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

9.  Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.

Authors:  Olaf R Mook; Frank Baas; Marit B de Wissel; Kees Fluiter
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

Review 10.  In vivo application of RNA interference: from functional genomics to therapeutics.

Authors:  Patrick Y Lu; Frank Xie; Martin C Woodle
Journal:  Adv Genet       Date:  2005       Impact factor: 1.944

View more
  76 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

Authors:  Jonathan E Zuckerman; Chung Hang J Choi; Han Han; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 3.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 4.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

Review 5.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

6.  LNA-based oligonucleotide electrotransfer for miRNA inhibition.

Authors:  Sophie Chabot; Julie Orio; Romain Castanier; Elisabeth Bellard; Søren J Nielsen; Muriel Golzio; Justin Teissié
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

7.  Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate.

Authors:  Abdulaziz M Aldayel; Hannah L O'Mary; Solange A Valdes; Xu Li; Sachin G Thakkar; Bahar E Mustafa; Zhengrong Cui
Journal:  J Control Release       Date:  2018-05-31       Impact factor: 9.776

8.  A ribonucleoprotein octamer for targeted siRNA delivery.

Authors:  Wanyi Tai; Junwei Li; Eva Corey; Xiaohu Gao
Journal:  Nat Biomed Eng       Date:  2018-07-12       Impact factor: 25.671

Review 9.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

10.  Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing.

Authors:  Mohamad Alameh; Myriam Jean; Diogo Dejesus; Michael D Buschmann; Abderrazzak Merzouki
Journal:  Int J Nanomedicine       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.